Achieve Life Sciences (ACHV) Other Accumulated Expenses (2013 - 2026)

Achieve Life Sciences has disclosed Other Accumulated Expenses across 14 years of filings, most recently posting $2.3 million for Q1 2026.

• Quarterly Other Accumulated Expenses rose 78.83% year-over-year to $2.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.3 million (up 78.83% YoY) and the FY2025 annual result came in at $6000.0, down 98.95% from the prior year.
• Other Accumulated Expenses rose to $2.3 million in Q1 2026, from $6000.0 in the prior quarter.
• Over five years, Other Accumulated Expenses peaked at $2.3 million in Q1 2026 and troughed at $6000.0 in Q4 2025.
• A 5-year average of $846235.3 and a median of $693000.0 in 2023 frame the typical range for Other Accumulated Expenses.
• Annual changes were most pronounced in 2022 — Other Accumulated Expenses surged 207.11% — and 2025, when it plunged 98.95%.
• Tracing ACHV's Other Accumulated Expenses over 5 years: stood at $403000.0 in 2022, then dropped by 12.9% to $351000.0 in 2023, then jumped by 63.25% to $573000.0 in 2024, then tumbled by 98.95% to $6000.0 in 2025, then soared by 38766.67% to $2.3 million in 2026.
• Business Quant data shows ACHV's Other Accumulated Expenses at $2.3 million in Q1 2026, $6000.0 in Q4 2025, and $1.8 million in Q3 2025.